TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04282499

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: combined exercise
Description: Patients will be undergone to aerobic exercises in addition to the resistance training.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: Patients will be trained through the aerobic exercises only.
Study: NCT00038116

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: embryonic dopamine cell implant surgery
Description: Half of the participants received the cell implant surgery, while the other half received the placebo. After the double-blind phase of the study, patients in the placebo group had the option of receiving tissue implants. Fourteen of these patients eventually had transplants.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sham surgery
Study: NCT02985385

Intervention type: OTHER
Intervention: Palliative management
Description: Diagnostic studies for abnormal fetal ultrasounds
Study: NCT01967082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APPSPIRE
Description: Given APPSPIRE app

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: Attend focus group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete survey
Study: NCT02243163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga exercise
Description: Subjects will receive regular 90-minutes yoga classes twice a week for 3 months.
Study: NCT02275052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC/VI DPI
Description: The DPI will contain a total of 30 doses. Each DPI will be comprised of two double-foil, laminate blister strips. Each blister of one strip will consist of 62.5mcg of UMEC blended with lactose and magnesium stearate while each blister of other strip will consist of 25 mcg of VI blended with lactose and magnesium stearate. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo DPI
Description: The placebo DPI, identical in appearance to the inhaler containing active study medication, will have two blister strips, each containing 30 blisters of lactose and magnesium stearate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salbutamol MDI
Description: Albuterol/salbutamol MDI (metered-dose inhaler) or nebules will be permitted throughout the study as rescue medication, for use as-needed. Albuterol/salbutamol will be sourced from local commercial stock or provided centrally from GlaxoSmithKline. Nebules will not be supplied.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salbutamol MDI
Description: Albuterol/salbutamol MDI (metered-dose inhaler) or nebules will be permitted throughout the study as rescue medication, for use as-needed. Albuterol/salbutamol will be sourced from local commercial stock or provided centrally from GlaxoSmithKline. Nebules will not be supplied.
Study: NCT03288987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab + FOLFIRI-3
Description: Bevacizumab 5 mg/kg will be administered at day 1 every 2 weeks. Initially, it will be administered as a 90-min infusion. If the first infusion is well tolerated, the second will be delivered as a 60-min infusion, and if the 60-min infusion is well tolerated, all subsequent infusions will be given over 30 minutes. FOLFIRI-3 regimen consists of irinotecan 100 mg/m2 over 1 hour at day 1, leucovorin 400 mg/m2 at day 1 followed by a 46 hour 5-FU continuous infusion (2000 mg/m2) and irinotecan 100 mg/m2 over 1 hour on day 3 will administer. Induction treatment was administrated every 2 weeks until disease progression, unacceptable toxicities, surgical intervention, or withdrawal of consent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab + FOLFIRI-3
Description: Bevacizumab 5 mg/kg will be administered at day 1 every 2 weeks. Initially, it will be administered as a 90-min infusion. If the first infusion is well tolerated, the second will be delivered as a 60-min infusion, and if the 60-min infusion is well tolerated, all subsequent infusions will be given over 30 minutes. FOLFIRI-3 regimen consists of irinotecan 100 mg/m2 over 1 hour at day 1, leucovorin 400 mg/m2 at day 1 followed by a 46 hour 5-FU continuous infusion (2000 mg/m2) and irinotecan 100 mg/m2 over 1 hour on day 3 will administer. Induction treatment was administrated every 2 weeks until disease progression, unacceptable toxicities, surgical intervention, or withdrawal of consent.
Study: NCT00600639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive mechanical ventilation using a BiPAP Vision or any other ICU ventilators with NIV option
Description: A mode of ventilation that does not require the insertion of the endotracheal tube, since the support is delivered throgh a full face or nasal mask

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard medical therapy plus oxygen that includes salbutamol, prednisolone and antibiotics as needed
Description: Standard medical therapy includes drugs like beta2-agonists, steroids, anthicolinergic agents- antibuiotics as needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard medical therapy that includes salbutamol, prednisolone and antibiotics as needed
Description: oxygen plus medical therapy for ARF
Study: NCT00574340

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperinsulinemic Hypoglycemic Clamp
Description: all participants received (2) hyperinsulinemic glucose clamp studies separated by 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperinsulinemic Hypoglycemic Clamp
Description: all participants received (2) hyperinsulinemic glucose clamp studies separated by 8 weeks
Study: NCT03026920

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: less invasive method
Description: The less invasive surgical method was conducted in this study. Then, the clinical results were compared with the patients treated using traditional methods to assess the less invasive method.
Study: NCT00237926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: aerobic or resistance training
Study: NCT01560013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone, oral 50 mg per day.
Study: NCT00495508

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quinine
Study: NCT01685476

Intervention type: DEVICE
Group type: OTHER
Intervention: Echodia® hand-held equipment
Study: NCT01444365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-652 NSAID
Description: ABT-652 capsules - 2 ABT-652 capsules twice daily (add-on) NSAID- as prescribed
Study: NCT00495508

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artemether / lumefantrine
Study: NCT02009501

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VAC VeraFlo with Dakins Instillation
Description: VAC VeraFlo with Dakins instillation will be placed in the operating room after surgical debridement. Biopsies will be obtained prior to surgical debridement, after surgical debridement, on day 4, and on day 7.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VAC Ulta Therapy
Description: VAC ULTA will be placed in the operating room after surgical debridement. Biopsies will be obtained prior to surgical debridement, after surgical debridement, on day 4, and on day 7.
Study: NCT01919749

Intervention type: OTHER
Group type: OTHER
Intervention: treated recommended
Description: Treatment will be recommended after reviewing the profiling analysis
Study: NCT01444365

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo NSAID
Description: Placebo - 2 placebo capsules twice daily NSAID- as prescribed
Study: NCT01681563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Lyophilized powder for intravenous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Liquid concentrate for solution for infusion.
Study: NCT01363128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study: NCT03933566

Intervention type: PROCEDURE
Intervention: Landmark-Based Superficial Cervical Plexus Block
Description: Landmark-Based Superficial Cervical Plexus Block
Study: NCT01651793

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caffeinated cocoa
Description: 70 mg caffeine, 179 mg theobromine, 499 mg flavanols, and 1 packet of Truvia sweetener

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa
Description: 21 mg caffeine, 179 mg theobromine, 499 mg flavanols, and 1 packet of Truvia sweetener

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: 473 ml brewed water containing 66 mg caffeine, caramel coloring and one packet Truvia sweetener
Study: NCT01363128

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Given IV
Study: NCT00552409

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 2000 IU by mouth daily for one year

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One softgel daily for one year
Study: NCT03163368

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant stereotactic radiosurgery
Description: Dose escalation of neoadjuvant stereotactic radiosurgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurosurgical resection
Description: Surgical resection of newly diagnosed brain metastases
Study: NCT01472211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: zinc enriching filter (LifeStrawFamily)
Description: filter purifies water and enriches it with zinc at 1-4 mg/l.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo filter
Description: filter purifies water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: disinfection tablets
Description: government promoted tablets disinfect water
Study: NCT00584129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-treatment swallowing exercises
Description: Swallowing exercises will be started pre-treatment with radiation.
Study: NCT01651793

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 473 ml of brewed water, caramel coloring and one packet Truvia sweetener
Study: NCT02490280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test
Description: The TSST is the gold standard social stress test and involves speaking in front of confederate judges and completing arithmetic tasks. The task takes 10-15 minutes.
Study: NCT03104855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d6-25-hydroxyvitamin D3
Description: intravenous administration of stable isotope-labeled D6-25(OH)D3
Study: NCT02886780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concentrated exposure treatment (cET)
Description: Psychological cognitive behavioral treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help
Study: NCT03539263

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifihappy
Description: During the six weeks of treatment, the experimental group will take daily doses of 2,5 g with a concentration of 4x109 CFU/sachet of a mixture of lyophilised probiotic strains of the following species:~* Lactobacillus fermentum~* Lactobacillus rhamnosus~* Lactobacillus plantarum~* Bifidobacterium longum
Study: NCT00584129

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post-treatment swallowing exercises.
Description: Patients to start swallowing exercises after completion of radiation therapy.
Study: NCT03214731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: Artesunate was produced by pharmaceutical factory for research specifically
Study: NCT01363128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT04003558

Intervention type: OTHER
Intervention: No interventions
Description: As this is a patient registry, there are no interventions.

Intervention type: OTHER
Intervention: No interventions
Description: As this is a patient registry, there are no interventions.

Intervention type: OTHER
Intervention: No interventions
Description: As this is a patient registry, there are no interventions.

Intervention type: OTHER
Intervention: No interventions
Description: As this is a patient registry, there are no interventions.
Study: NCT03917732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive training
Description: The cognitive training the investigators are planning consists of three modules which, in their entirety, are intended to help improve bladder dysfunction, which leads to psychological distress in patients: psychoeducation, training of cognitive functions and training in behavioural therapeutic techniques.~The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pelvic floor training
Description: At the beginning of the training, perception of the pelvic floor is the most important factor. The patients should learn the motor skills to consciously perceive and feel the pelvic floor muscles. This requires a lot of concentration and movement control. After this perception phase, the learned movements are internalized. The fine coordination of the pelvic floor muscles is more harmonious and the tensing and relaxing of the muscles becomes easier over time. In the last phase of the training, the movements and muscle activations should be internalised in such a way that they are anchored as automated movement patterns.~The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes.
Study: NCT01186809

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: in vitro expanded Cytokine Induced Killer (CIK) cells
Description: Three infusions of donor Cytokine Induced Killer (CIK) cells will be administered according to a dose escalating program, starting 3 weeks after second Donor Lymphocyte Infusions (DLI). Cytokine Induced Killer administrations will be separated by 3 weeks intervals
Study: NCT04012359

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung ultrasound
Description: Non-invasive external ultrasonography of the chest wall

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung ultrasound
Description: Non-invasive external ultrasonography of the chest wall

Intervention type: DIAGNOSTIC_TEST
Intervention: Chest radiography
Description: Chest radiography to search for visible pleural edge, synonym with persistent pneumothorax

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary function tests
Description: Pulmonary function evaluation as part of routine care for emphysematous patients

Intervention type: OTHER
Intervention: Clinical examination
Description: Standard clinical examination performed by investigating physician

Intervention type: OTHER
Intervention: Clinical examination
Description: Standard clinical examination performed by investigating physician
Study: NCT03590496

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium-Propionate 500mg
Description: Calcium-Propionate capsules

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules without any active ingredient
Study: NCT01959776

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vitrectomy
Study: NCT03811665

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation
Description: RFA probe will create an ablation zone of a 1.0 cm diameter beyond the maximum CT-measured tumor diameter. The generator will modulate power up to 150 W in reach average ablative temperature of 105oC. Tumors will be treated for two cycles of 8 minutes duration each upon reaching target temperatures.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactive body radiation therapy
Description: The Gross Tumour Volume (GTV) is defined as the visible tumour seen on the planning CT simulation. No clinical target volume (CTV) for microscopic disease is necessary. The internal target volume (ITV) accounts for changes in tumour position due to respiration, and is assessed on 4DCT. The planning target volume (PTV) will be a standard 0.5 cm around the ITV.
Study: NCT02236611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium
Description: Umeclidinium 62.5 mcg will be available as dry inhalation powder to be taken using a nDPI
Study: NCT03716206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exergame
Description: This intervention included upper limb task-orientation training, upper limb coordination training, shoulder range of motion and upper limb activity training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: This intervention included upper limb task-orientation training, upper limb coordination training, shoulder range of motion and upper limb activity training.
Study: NCT01623492

Intervention type: OTHER
Intervention: Subjects with diagnosis of Eisenmenger Syndrome
Description: 1. Antibiotic recommendation for SBE prophylaxis and influenza vaccine~2. Contraception counseling, and recommendations regarding avoidance of pregnancy~3. Documentation and prescription of the specific medications:~   1. Oxygen~  2. Diuretic~  3. ASA, Anticoagulant~  4. CCB, BB, ACEI, ARB~  5. Iron Supplementation~  6. Allopurinol~  7. PAH specific therapy
Study: NCT03984643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vim-Deep Brain Stimulation
Description: This study consists of testing additional model-derived DBS settings during initial and regular follow-up clinical visits every 6 months for up to 2 years in which individuals with DBS implants are re-evaluated by a clinician to make sure that the stimulation settings employed during the previous clinical visit remain therapeutic. It is important to note that this study is post-surgical and all procedures (i.e. stimulation settings that will be tested in the clinic) are within the FDA-approved range of stimulation settings available on the implanted pulse generator.
Study: NCT02939196

Intervention type: PROCEDURE
Intervention: office hysteroscopy 3.7
Description: office hysteroscopy with a 3.7 -mm outer sheath

Intervention type: PROCEDURE
Intervention: office hysteroscopy 4
Description: office hysteroscopy with a4-mm outer sheath
Study: NCT02243189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-43260295
Description: A single nasal dose of JNJ-43260295, 6400 microgram, will be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-43260295
Description: A single nasal dose of JNJ-43260295, 6400 microgram, will be given.
Study: NCT03539263

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the six weeks of treatment, the experimental group will take daily doses of 2,5 g of maltodextrin
Study: NCT02243189

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single nasal dose of placebo matching to JNJ-43260295 will be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Allergen Challenge
Description: Participants will be challenged by the nasal route with an appropriate allergen based on skin test reactivity.
Study: NCT03297554

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: m-Health Intervention
Description: Parent/child dyads attend remote counseling sessions delivered over Internet-connected device (e.g. smartphone, iPad/tablet, laptop, or desktop computer). A counselor will deliver the lesson, review progress based on the objectively measured data, and provide individualized advice and problem-solving strategies for parent and child. Families will receive weekly contact via smartphone. Each lesson will include an interactive component for parent and child related to healthy eating and active play, as well as an interactive parenting training component. Lessons are based on the family treatment methods that effectively promote child and parent weight loss that is sustained for 10 years (Epstein et al., 1990; Epstein et al., 1981).
Study: NCT02236611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium
Description: Glycopyrronium bromide will be available as inhalation capsules, 44 mcg per capsule, taken using BREEZHALER inhalers
Study: NCT04012242

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound application
Description: Shear wave elastography, shear wave dispersion, attenuation imaging, and intensity analysis
Study: NCT01256359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel and AZD6244
Description: Docetaxel 75mg/m2 IV and AZD6244 75mg bd daily. Docetaxel will be administered every 3 weeks for a maximum 6 cycles, but AZD6244 may be continued beyond this, until disease progression.
Study: NCT03214731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: Artesunate was produced by pharmaceutical factory for research specifically

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo was produced by pharmaceutical factory for research specifically